The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics.

Proteomic patterns in serum that discriminate between malignant and benign ovaries may provide a powerful tool for screening in high risk women.

[1]  C. Perez,et al.  Principles and Practice of Gynecologic Oncology , 1992 .

[2]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[3]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[4]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[5]  R. Bast,et al.  Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers , 1995, Cancer.

[6]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[7]  G. Mills,et al.  Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. , 2001, Journal of the National Cancer Institute.

[8]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.

[9]  R. Edwards.  Tribute to Patrick Steptoe: beginnings of laparoscopy. , 1989, Human reproduction.

[10]  R. Berkowitz,et al.  Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.

[11]  Daniel S. Miller,et al.  The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer , 2000, Cancer.